1 / 12

Verluma

Verluma. Nofetumomab Merpentan (Fragment). Indications. For the detection and staging of previously untreated small cell lung cancer. It must be confirmed via biopsy confirmed. Radiopharmaceutical and Dose. 5-10 mg Verluma labeled with 15-30 mCi Tc99m in 15-20ml

gbrink
Download Presentation

Verluma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Verluma Nofetumomab Merpentan (Fragment)

  2. Indications • For the detection and staging of previously untreated small cell lung cancer. It must be confirmed via biopsy confirmed

  3. Radiopharmaceutical and Dose • 5-10 mg Verluma labeled with 15-30 mCi Tc99m in 15-20ml • Administered over 3-5 minutes • Kit is good for 6 hours

  4. Method of Localization and Excretion • Recognizes glycoprotein cancer associated antigen expressed on a variety of tumors. • 64% renal clearance in 22 hours • Secondary route hepatobiliary

  5. Precautions and Patient Prep • Possibility of HAMA response • Well Hydrate • Bowel Prep • Use filters/filtered needles during dose preparation and injection.

  6. Scanning • 14-17 hours post injection • Normally inject at 5pm and image at 7am • HIRES/LEAP • 15% Window 140keV • SPECT • 360o • 64 stops • Anterior and Posterior • 500K or 10 minutes • Head to pelvis • Lateral skulls

  7. Normal Gallbladder Intestine Kidneys Bladder Pituitary gland Testes Thyroid Salivary glands Abnormal Hot spot late images cold center, hot ring early images Uptake other than known tumors, inflammation, recent surgery sites, skin folds Findings

  8. False Positive Areas of increased blood flow such as infection/inflammation False Negative Usually brain, bone and small liver lesions False Readings

  9. Survival Rate • Extensive disease • Distant mets located • 0-2% survival rate • Chemotherapy only • Limited disease • No mets located • 2 year survival rate • Chemotherapy and Radiation Therapy

  10. Findings Verluma is a monoclonal antibody Fab fragment linked to 99mTc. Verluma identifies advanced-stage disease in patients with small-cell lung cancer (SCLC). The determination of disease stage has important prognostic and therapeutic implications. In the clinical trial involving 89 patients with confirmed SCLC, Tc-labeled Verluma accurately determined whether the disease was extensive or limited 82 percent of the time. If the test indicated extensive disease, the result was true in 94 percent of the patients. However, if the test indicated limited disease, it was less valuable as a diagnostic aid, failing to image tumors in some body organs in approximately 23 percent of the patients. Because of these false negative readings, additional standard diagnostic tests, such as a bone or CT scan or a bone marrow biopsy should be performed when limited disease is found. Verluma was approved August 20, 1996. this document was a handout at a biweekly inservice training at Beth Israel Deaconess Medical Center Nuclear Medicine Department led by Jeff Cone.

  11. Findings Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9298295&dopt=Abstract

  12. Return to the Table of Content

More Related